Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Alnylam and UT Southwestern to develop RNAi therapeutics for high cholesterol

July 20, 2006

BioLineRx inlicenses orally available peptide for treatment of obesity

July 19, 2006

ConjuChem places DAC:GRF program in HIV lipodystrophy on clinical hold

July 19, 2006

New therapeutic agents for hematological disorders disclosed in recent Nissan patent

July 18, 2006

Implanon, first FDA approved single-rod implantable contraceptive

July 18, 2006

Positive pharmacological and safety profile of Hematide in preclinical studies

July 18, 2006

First patients complete follow-up in phase I/II study of BDM-E

July 18, 2006

Daiichi Sankyo and Lilly sign European agreement for Evista

July 18, 2006

Amgen's calcium-sensing receptor agonist AMG-641 beneficial in hyperparathyroidism secondary to CKD

July 17, 2006

MED-205 shows cholesterol-lowering activity in cholesterol animal model

July 17, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...